Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions.

非酒精性脂肪肝 (NAFLD) 是一种多方面的疾病，与各种代谢紊乱、肥胖和生态失调有关。肠道微生物群在 NAFLD 和其他代谢紊乱的发病机制中起着重要作用。然而，最近的科学热潮强调有益肠道微生物群和细菌疗法在 NAFLD 管理中的作用。粪便微生物群移植 (FMT) 是现代治疗方法，采用最先进的方法治疗 NAFLD。其他潜在疗法包括益生菌和益生元补充剂，它们基于改变肠道微生物来治疗 NAFLD。在这篇综述中，我们主要关注肠道微生物群与 NAFLD 进展的病理关联，